Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Empagliflozin (25mg) + Linagliptin (5mg)
Therapeutic Category
Antidiabetic, Cardiology, ENDOCRINOLOGY and Hormonal range, Endocrinology
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*10
Price
₹345/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Emplozin L 25/5 Tablet is a fixed-dose combination of Empagliflozin (25mg) and Linagliptin (5mg), specifically designed for the effective management of type 2 diabetes mellitus. This dual-action therapy combines an SGLT2 inhibitor and a DPP-4 inhibitor to help control blood glucose levels, address common complications, and improve overall metabolic control.
By targeting different mechanisms, Emplozin L 25/5 Tablet provides comprehensive diabetes management, supporting better blood sugar control and enhancing overall patient outcomes.
Common side effects include upper respiratory tract infections, headache, nausea, and urinary tract infections. Serious side effects may involve kidney problems, hypotension, and dehydration.
Emplozin L 25/5 Tablet is indicated for type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control, particularly in patients inadequately controlled on other oral anti-diabetic therapies.
Consult your healthcare provider if you have a history of kidney disease or heart conditions before using this medication. Not recommended during pregnancy or breastfeeding.
Store at room temperature (15°C-30°C) in a dry place, away from light and moisture.
Composition : Bromfenac (0.09% w/v) + Moxifloxacin (0.5% w/v)
Composition : Bromfenac (0.9mg) Eye Drops
Composition : Carboxymethylcellulose (3mg/ml) + Glycerin (10mg/ml) + n-acetylcarnosine (10mg/ml)
Composition : Dexamethasone (0.1% w/v) + Tobramycin (0.3% w/v)
Composition : Fluconazole (0.3% w/v)
Composition : Gatifloxacin (0.3% w/v)
Composition : Ketorolac (0.4% w/v) + Olopatadine (0.1% w/v)
Composition : Ketorolac (0.5% w/v)
Composition : Ketorolac (5% w/v) + Moxifloxacin (0.5% w/v)
Composition : Loteprednol etabonate (0.5% w/v)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This advanced anti-diabetic combination is widely used in type 2 diabetes management, making it a high-demand prescription product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in type 2 diabetes, blood sugar control, insulin resistance management, cardiovascular risk reduction support, and long-term glycemic management. It is commonly prescribed by diabetologists and physicians for patients requiring dual-action therapy.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Empagliflozin 25mg + Linagliptin 5mg Tablets with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from strong chronic prescription demand, growing diabetic patient populations, repeat monthly therapy usage, and high acceptance in diabetology and general medicine segments when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this anti-diabetic formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.